The hypolipidaemic agent pravastatin differs from other US Food and Drug Administration
(FDA)-approved HMG-CoA reductase inhibitors (eg lovastatin and simvastatin) because it …

Pravastatin, one of the 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase
inhibitors (statins) widely used in the management of hypercholesterolaemia, has unique …

Pravastatin, lovastatin and simvastatin are HMG-CoA reductase inhibitors with very similar
structures. However, minor substitutions in the decalin ring have resulted in major …

The oral bioavailability of two HMG‐CoA reductase inhibitors, pravastatin and lovastatin,
was investigated in this randomized, two‐way crossover study. Twenty healthy men were …

The disposition of a single 20‐mg oral dose of pravastatin was assessed in subjects with
various degrees of renal function. Sixteen subjects (13 males, 3 females) with creatinine …

The pharmacokinetics, pharmacodynamics, and safety of pravastatin, a new selective 3‐
hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitor, were evaluated during …

Twelve healthy male volunteers received single market‐image 40‐mg oral doses of
lovastatin and simvastatin (both lactone prodrugs), or pravastatin (α β‐hydroxyacid) at 1 …

Synopsis Pravastatin is an HMG-CoA reductase inhibitor which lowers plasma cholesterol
levels by inhibiting de novo cholesterol synthesis. Pravastatin produces consistent dose …

The chemistry, pharmacology, pharmacokinetics, clinical trials, adverse effects, role in lipid-
lowering therapy, and dosage and administration of pravastatin are reviewed. Pravastatin …

Cerivastatin sodium, a novel statin, is a synthetic, enantiomerically pure, pyridine derivative
that effectively reduces serum cholesterol levels at microgram doses. Cerivastatin is readily …